High tumor amplification burden is associated with


Journal

Cancer biology & therapy
ISSN: 1555-8576
Titre abrégé: Cancer Biol Ther
Pays: United States
ID NLM: 101137842

Informations de publication

Date de publication:
31 12 2022
Historique:
entrez: 28 9 2022
pubmed: 29 9 2022
medline: 1 10 2022
Statut: ppublish

Résumé

Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications - "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with

Identifiants

pubmed: 36171565
doi: 10.1080/15384047.2022.2128608
pmc: PMC9542347
doi:

Substances chimiques

Biomarkers, Tumor 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Subventions

Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States

Références

Cancer Cell. 2021 Feb 8;39(2):154-173
pubmed: 33125859
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Cancer Biol Ther. 2020;21(1):95-100
pubmed: 31564192
Biomol Concepts. 2013 Dec;4(6):567-82
pubmed: 25436757
Philos Trans R Soc Lond B Biol Sci. 1995 Jan 30;347(1319):49-56
pubmed: 7746853
Nat Commun. 2020 Oct 2;11(1):4965
pubmed: 33009371
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Gynecol Oncol. 2021 Apr;161(1):113-121
pubmed: 33541735
Mol Cancer Ther. 2016 Oct;15(10):2475-2485
pubmed: 27466356
Nucleic Acids Res. 1994 Sep;22(17):3551-5
pubmed: 7937055
Nature. 1989 Dec 7;342(6250):705-8
pubmed: 2531845
J Mol Biomark Diagn. 2017 Sep;8(5):
pubmed: 29285416
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32493840
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Cell Death Differ. 2018 Jan;25(1):133-143
pubmed: 29125602
Trends Cancer. 2021 Jan;7(1):15-28
pubmed: 33008795
J Hematol Oncol. 2021 Dec 2;14(1):201
pubmed: 34857015
Trends Genet. 2006 Aug;22(8):447-55
pubmed: 16787682
Adv Exp Med Biol. 2005;570:343-61
pubmed: 18727507
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Genome Med. 2021 Oct 4;13(1):155
pubmed: 34607609
Cell Rep. 2019 Sep 10;28(11):3010
pubmed: 31509758

Auteurs

Rushikesh S Joshi (RS)

School of Medicine, University of California San Diego, La Jolla, CA, USA.

Amelie Boichard (A)

Department of Molecular Cancer Genetics, University of Strasbourg Hospitals, Strasbourg, France.

Jacob J Adashek (JJ)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, USA.

Razelle Kurzrock (R)

MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, WIS, USA.
Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Paris, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH